Lundbeck’s Schizophrenia Drug Fails to Win U.S. Panel Backing

[Guest guest]

Lundbeck's Schizophrenia Drug Fails to Win U.S. Panel Backing

Share | Email | Print | A A A

By Olmos

April 7 (Bloomberg) -- H. Lundbeck A/S's proposed treatment for schizophrenia

failed to win the recommendation of a U.S. advisory panel, which cited concern

over safety of the drug that has been linked to a possible risk of sudden

cardiac death.

A committee of outside advisers reviewing the drug for the Food and Drug

Administration voted 12-1 that the Copenhagen- based drugmaker's Serdolect was

insufficiently safe for the " broad treatment " of schizophrenia. The panel,

meeting today in Silver Spring, land, said the medication may be " acceptably

safe " for a smaller group of patients, though it did not specify which patients

that might include.

To contact the reporter on this story: Olmos in San Francisco at

dolmos@....

Last Updated: April 7, 2009 16:52 EDT